Compare Newmont Corporation (NEM) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Newmont Corporation (NEM) trades at $113.54, down 2.45% over 24 hours, with technical indicators showing a bearish short-term trend. The company reported strong fundamentals, including record free cash flow of $5.3 billion in H1 2026 (Defense World, 2026-10-01) and consistent earnings beats in recent quarters. Revenue grew to $22.67 billion in 2025, with net income margin improving to 31.25%. Analyst sentiment remains positive, with a consensus price target of $136.83 and 76% buy ratings.

The outlook for NEM is supported by robust cash flow generation and operational improvements, but near-term price pressure exists from technical bearish signals and gold price volatility. Investment appeal lies in its valuation metrics, such as a P/E of 14.57, and shareholder returns via dividends. Key risks include sensitivity to gold prices and execution of growth projects. The stock offers value for long-term investors despite current market weakness.

DENTSPLY SIRONA (XRAY) trades at $8.54, near its 52-week low, with bearish technical indicators and mixed fundamentals. The company reported Q2 2026 EPS of $0.52 beating expectations but revenue declined 4.1% year-over-year. Net income remains negative at -$598 million for 2025, though margins show slight improvement. Analyst consensus is mixed with 37.5% buy ratings but a $13.40 price target suggesting 57% upside potential from current levels.

The stock presents a high-risk turnaround opportunity with significant upside if management's restructuring efforts succeed, but faces headwinds from declining sales, margin pressure, and competitive challenges in dental markets. Institutional ownership changes and ongoing transformation investments create both uncertainty and potential for recovery.